Latest Influenza research Stories
QUEBEC CITY, Dec. 11, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a non-refundable contribution of up to $493,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will support the development of...
OTTAWA, Dec. 3, 2012 /CNW/ - On the opening day of the 10(th) Canadian Immunization Conference, the Honourable Leona Aglukkaq, Minister of Health, announced two important initiatives to protect Canadians from infectious diseases. "Immunization lays the foundation for good health in this country," said Minister Aglukkaq. "That is why we are renewing our commitment to a leading influenza research network and launching an updated, online edition of the Canadian Immunization Guide."...
TUEBINGEN, Germany, Nov. 25, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases. In vivo data published by...
BLUE BELL, Pa., Nov. 14, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania (UPenn), adding worldwide rights to technology and intellectual property for novel synthetic vaccines against cancer, infectious diseases and potential biodefense pathogens. These technologies were developed by UPenn Professor David B. Weiner and collaborators. Dr. Weiner is a pioneer in the field of DNA vaccines,...
SWIFTWATER, Pa. and BALTIMORE, Nov. 2, 2012 /PRNewswire/ -- Sanofi Pasteur will bring its Fluzone(®) Intradermal Vaccine Coop de Quill VacciNation Tour to Baltimore on Friday, Nov. 2, as part of its cross-country efforts to raise awareness about the seriousness of influenza and the various vaccine options that are available for adults 18 through 64 years of age this flu season. In an effort to help improve flu immunization rates, Sanofi Pasteur's Fluzone Intradermal Vaccine Coop...
Canadians urged to protect themselves for the coming flu season. Video: B-Roll - October 31, 2012: John Dorsey Head, Vaccines and Diagnostics at Novartis Pharmaceuticals Canada Inc. receiving Agriflu(®) influenza vaccine. Video available here. DORVAL, QC, Oct. 31, 2012 /CNW/ - Novartis Pharmaceuticals Canada Inc. has announced it is resuming distribution of two seasonal influenza vaccines in Canada, Fluad(®) and Agriflu(®), following the announcement by Health Canada earlier...
NES ZIONA, Israel, October 22, 2012 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) today announced that the Company has passed successfully a 2 day QP GMP audit during which the Company`s manufacturing facility, production process, personnel and quality control procedures were examined in great detail. This demanding certification is a requirement for Companies intending to manufacture a clinical grade product for human trials anywhere in Europe and gives the...
SWIFTWATER, Pa., Oct. 22, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV). Three clinical trials have been conducted to evaluate the safety and the immune response to the quadrivalent influenza vaccine in children, adults and the elderly. All three studies demonstrated that the safety and immunogenicity...
SWIFTWATER, Pa., Oct. 18, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone(® ) (Influenza Virus Vaccine). The sBLA file has been accepted by the FDA for full review, and an action date is anticipated in the second quarter of 2013. "The...
SAN DIEGO, Oct. 17, 2012 /PRNewswire/ -- Pfenex Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) under its Broad Agency Announcement entitled "Vaccine Technologies to Advance Next Generation Anthrax Vaccines" (BAA-NIAID-DMID-NIHAI2010104) has awarded Pfenex a contract to develop an alternative delivery method for Pfenex's recombinant Protective Antigen (rPA)-based anthrax vaccine. NIAID, part of the National Institutes of Health, has made an...
